What Baysient does

Baysient LLC is a privately held US software company headquartered in Fort Myers, Florida, that builds cloud-based precision dosing software for anti-inflammatory monoclonal antibody (MAb) therapies used in conditions such as inflammatory bowel disease (IBD). Its core product, iDose, applies a proprietary "Compuceutical" methodology — combining Bayesian pharmacokinetic models with routine lab results (drug levels, anti-drug antibodies) and patient demographic data — to help physicians calculate individualized doses targeted to a specific trough level. The platform is FDA-regulated and protected by patents covering iDose and the T3 (Time to Target) module; a companion module, Tuminimize, supports dose optimization. The latest release, iDose GEN7.0 (February 2026), expanded coverage to 17 inflammatory disease indications and added predictive analytics tools.

Baysient sells on a subscription basis to two primary customer segments: enterprise healthcare organizations (sold via direct/enterprise sales motions) and individual physicians (served through a demo-driven self-service flow). Federal law requires the software to be used by or under the supervision of a healthcare professional, and pricing is quote-based and not publicly disclosed. The company has 11-50 employees, no disclosed institutional funding or parent company, and a named team of seven led by PhD-level Chief Science Officer Diane R. Mould. Distribution is currently domestic (United States), and the company relies on a digital-first marketing approach (website, blog, video, LinkedIn/Twitter/Facebook) to drive physician education and demo requests.

The business model is best characterized as a niche, regulated clinical SaaS targeting a high-acuity but narrow prescriber base (specialists managing anti-TNF therapy). Its revenue mechanics depend on subscription renewals from physicians and healthcare organizations, with growth levers tied to indication expansion, regulatory clearance for new biologics, and penetration into additional inflammatory disease specialties.

Name

Baysient

Legal name

Baysient LLC

Website

https://baysient.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Baysient LLC is a US-based clinical SaaS company that sells FDA-regulated, cloud-based precision dosing software (iDose) using Bayesian pharmacokinetic models to help physicians individualize anti-inflammatory monoclonal antibody therapy for patients with inflammatory diseases such as IBD.

Ownership category

akta.pro rank

Product category

Precision Dosing Software

NAICS

Computer Systems Design and Related Services (54151), Health Care and Social Assistance (62)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

Keywords

• Precision dosing software
• Therapeutic drug monitoring
• Bayesian dosing platform
• Biologic therapy optimization
• Clinical decision support

Headquarters

HQ city

Fort Myers

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software Subscription (iDose Platform): Baysient appears to operate on a subscription basis for healthcare organizations and physicians accessing the iDose precision dosing platform. The software is regulated by the FDA and provided as a cloud-based service requiring individual account provisioning under healthcare professional supervision.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Baysient develops and sells iDose®, a cloud-based, FDA-regulated software platform that uses Bayesian models, routine lab results, and demographic information to help physicians calculate individualized doses of anti-inflammatory monoclonal antibodies (MAbs) to specific target trough levels for patients with inflammatory diseases such as IBD. The core iDose platform is complemented by companion modules Tuminimize™ (dosing protocol optimization) and T3® Time to Target (time-to-target trajectory planning), with subscriptions sold to healthcare organizations and individual physicians.

Product overview

Baysient offers a unified precision dosing platform built around its core product iDose®, supported by companion modules Tuminimize™ and T3® (T3 Time to Target®). The platform utilizes a pioneering Compuceutical approach combining Bayesian models, routine lab results, and demographic information to enable individualized dosing of anti-inflammatory monoclonal antibodies. The platform has expanded to cover 17 inflammatory disease indications and is FDA-regulated. iDose® serves as the primary integrative software, while Tuminimize™ optimizes dosing protocols and T3® addresses time-to-target treatment planning.

Differentiator

Problem solved

Functional benefit

Brands

• iDose®: Integrative, cloud-based software that facilitates individualized dosing of all marketed MAbs used to treat inflammatory diseases.
• Tuminimize™
• T3®

Products and services

• iDose® Integrative, cloud-based, FDA-regulated software that uses Bayesian models, routine lab results, and demographic information to facilitate individualized dosing of all marketed anti-inflammatory monoclonal antibodies (MAbs) used to treat a wide range of inflammatory diseases. Used by physicians and healthcare organizations under medical supervision.
• Tuminimize™

Quantifiable outcome

• Up to half of patients on anti-TNF therapy experience secondary loss of response, much of which is pharmacokinetic and addressable through precision dosing

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Prometheus Biosciences: Prometheus (acquired by AbbVie in 2023) pioneered companion-diagnostic / TDM-style testing for IBD biologics. Although now part of a large pharma, it is the historical reference point in IBD therapeutic drug monitoring and a benchmark for the value of precision-dosing data in inflammatory bowel disease.
• Quest Diagnostics: Quest Diagnostics provides routine and specialty TDM testing services, including biologic level and anti-drug antibody assays relevant to anti-TNF therapy. As a scaled clinical lab it is a comparable TDM data source and a potential partner or competitor to Baysient.
• ARUP Laboratories: ARUP is a large academic reference laboratory that offers specialized TDM and biologic monitoring assays used by gastroenterologists and rheumatologists. It functions as a leading TDM competitor / data source across the same anti-TNF monitoring niche as Baysient.
• Labcorp Drug Development / Labcorp Diagnostics: Labcorp operates a broad reference-laboratory network including therapeutic-drug-monitoring assays used by IBD and rheumatology prescribers. It represents the incumbent lab-based TDM channel that Baysient's software-anchored model is partially substituting.

Others

• Oracle Health (formerly Cerner): Oracle Health provides large-scale EHR and population-health infrastructure across U.S. hospitals and IDNs. As with Epic, it is not a direct competitor in Bayesian dosing but represents an adjacent health-IT incumbent that could integrate or displace point solutions like Baysient at the enterprise tier.
• Epic Systems: Epic is the dominant EHR vendor for large U.S. health systems and a frequent channel for third-party clinical-decision-support tools. It does not directly dose biologics today but is the obvious embedding point that could host, replace, or block third-party dosing apps like iDose.

Emerging players

• Satisfai Health: Satisfai Health builds AI tools for gastroenterologists with a focus on IBD and GI-related clinical workflows. It is comparable to Baysient as a digital-health vendor aiming to embed evidence-based software into the IBD treatment pathway.
• Iterative Health: Iterative Health is an AI/SaaS company focused on gastroenterology, including IBD-related clinical decision support and endoscopy workflows. It targets the same IBD-prescribing physician base Baysient serves, but addresses different pain points (imaging/AI) rather than dosing.
• Virgo Surgical Solutions: Virgo provides cloud-based endoscopy video capture and AI analytics for GI practices. It overlaps with Baysient's gastroenterology buyer segment and represents an adjacent point-of-care SaaS play in IBD-relevant specialty care.

Direct peers

• DoseMe: DoseMe (acquired by Tabula Rasa HealthCare / now part of CareVention HealthCare) offers a Bayesian model-based, cloud precision-dosing SaaS for clinicians. It is the most directly comparable competitor to Baysient's iDose platform in technology architecture, dosing methodology, and subscription go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/baysient
• Facebookfacebook.com/baysient
• LinkedInlinkedin.com/company/baysient-biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baysient